UK-based biotech startup Genie Fertility has officially launched from stealth mode after securing $1.22 million in pre-seed funding to advance its pioneering work in reproductive health. The funding will go toward developing what the company says is the world’s first non-invasive fertility diagnostic for uterus health, alongside further research through its machine learning-driven biomarker discovery platform.
The investment round drew participation from Tiny VC, 33East VC, Arben Ventures, Transpose Platform, and Entrepreneur First, with backing from both US and European investors. Genie Fertility is already collaborating with leading IVF groups across the UK and Europe, supported by medical advisors from Imperial College London and Harvard Medical School.
According to the company, its research has identified a number of novel fertility markers in the uterus lining that can be improved through existing medical interventions.
“The health of the uterus lining accounts for up to 25% of fertility issues, but it has long been a blindspot for clinicians because it can only be accessed through an invasive and painful biopsy,” said Anoushka Menon, CEO of Genie Fertility. “Our pain-free non-invasive diagnostic changes that.”
Genie’s multi-omics discovery platform, powered by machine learning, is built on data from more than 200,000 fertility patients. Its first diagnostic test analyses a range of molecular markers in the uterus lining through menstrual blood, which the company describes as a rich, untapped source of reproductive health information.
“IVF is the gold-standard treatment for infertility, which affects 1 in 6 couples, but it fails 73% of the time and requires urgent innovation.” said Dr Andreas Hadjimitsis, Co-Founder and CTO of Genie Fertility. “A lot of the focus in fertility has been on sperm, egg and embryo health. We want to create a world where the uterus gets the same attention.”
The startup aims to use its discovery platform not only for diagnostics but also to develop targeted therapeutics that can address long-overlooked reproductive health conditions. By offering clinicians a pain-free, data-driven approach, Genie Fertility hopes to improve outcomes for millions of women who face fertility challenges and related conditions.
The fresh funding will support the scientific development and validation of Genie Fertility’s first diagnostic product, as well as initial work on expanding its AI-driven discovery platform. Through continued collaboration with IVF partners and medical experts, the company plans to accelerate innovation in reproductive medicine and redefine how uterine health is understood and treated.
